Hooray - you make me feel soooo good - "the science is great". I appreciate that! It endorses that my investment based on actually using the BIEL science on my sprained ankle was not isolated.
If one follows up on the Advisory Commitee to the FDA recommending the end of acetominophen because of liver damage (see the posts last week)do you not think it makes sense for J&J to acquire BIEL? If I'm the J&J CEO, I'm all over Whelan! If I'm CEO of a J&J competitor, I'm in the game to get BIEL and save my company.
Or even better, to do a JV with BIEL and therefor monolize the OTC the pain control market?
That way the Whelan knockers and management knockers would still have a whipping boy and ActiPatch etc., sales would fly off the charts and the investors win big time.
If you had gone to regulators 40 years ago with ActiPatch, you would not have had a reply, you would have been laughed at. Now, we have FDA approval of BIEL's RecoveryRx device by Rx only and applications to go OTC for other indications. Is there not now a specific group handling devices? Americans are getting sick of the damages caused by popping pills. I think BIEL's time has come.
There are hundreds of examples of drugs being launched as Rx and moving to OTC a few years later - Zantac from GSK for ulcers is a perfect example. First by precription, then like candy. The FDA knows what it is doing, we must be patient and BIEL management must be quiet.
Unlike others, I am not interested in promoting some guy's company or share price. I am simply sharing that ActiPatch worked for me amazingly well. For me it was just common sense to risk a few bucks in BIEL shares based on the common sense of it all. As you say, it's about the science, we can all forget about Whelan and anyone else.
